Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ra Capital Management, L.P. sold 170,441 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $0.40, for a total transaction of $68,176.40. Following the completion of the sale, the insider directly owned 349,907 shares of the company’s stock, valued at $139,962.80. The trade was a 32.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $55,361.25.
- On Monday, June 15th, Ra Capital Management, L.P. sold 128,770 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.39, for a total transaction of $50,220.30.
- On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total transaction of $99,751.14.
- On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $16,991.51.
- On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $136,826.00.
- On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $64,736.64.
- On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $58,618.30.
- On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total transaction of $267,333.46.
Werewolf Therapeutics Stock Performance
HOWL stock traded down $0.03 during mid-day trading on Tuesday, hitting $0.36. The company had a trading volume of 580,233 shares, compared to its average volume of 468,701. The firm has a market cap of $17.50 million, a PE ratio of -0.29 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 12 month low of $0.36 and a 12 month high of $2.38. The stock’s fifty day moving average price is $0.65 and its two-hundred day moving average price is $0.71.
Wall Street Analyst Weigh In
Several analysts have commented on HOWL shares. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $3.75.
Check Out Our Latest Analysis on HOWL
Hedge Funds Weigh In On Werewolf Therapeutics
Several hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its stake in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Vanguard Group Inc. grew its stake in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Renaissance Technologies LLC grew its stake in Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after acquiring an additional 221,766 shares in the last quarter. Jane Street Group LLC purchased a new position in Werewolf Therapeutics during the second quarter valued at approximately $409,000. Finally, Citadel Advisors LLC purchased a new position in Werewolf Therapeutics during the third quarter valued at approximately $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Read More
- Five stocks we like better than Werewolf Therapeutics
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
